• 1. Metabolomic estimation of the diagnosis of hepatocellular carcinoma based on ultrahigh performance liquid chromatography coupled with time-of-flight mass spectrometry
  Yuan-Feng Li,Shi Qiu,Li-Juan Gao,Ai-Hua Zhang RSC Adv. 2018 8 9375
• 2. Synthesis of 3-(2-acetylaminoethyl)-6-hydroxy-5-methoxyindole (6-hydroxymelatonin)
  D. E. Hall,A. H. Jackson J. Chem. Soc. C 1967 1681
• 3. Assessing melatonin and its oxidative metabolites amounts in biological fluid and culture medium by liquid chromatography electrospray ionization tandem mass spectrometry (LC–ESI-MS/MS)
  Mirela B. Coelho,Maria Carolina Rodrigues-Cunha,Christina R. Ferreira,Elaine C. Cabral,Guilherme P. Nogueira,Marcos N. Eberlin,Claudia L. V. Leal,Rosineide C. Simas Anal. Methods 2013 5 6911
• 4. Theoretical insight into the antioxidant properties of melatonin and derivatives
  Jeffrey R. Johns,James A. Platts Org. Biomol. Chem. 2014 12 7820
• 5. Secondary electrospray ionization coupled to high-resolution mass spectrometry reveals tryptophan pathway metabolites in exhaled human breath
  Diego García-Gómez,Thomas Gaisl,Lukas Bregy,Pablo Martínez-Lozano Sinues,Malcolm Kohler,Renato Zenobi Chem. Commun. 2016 52 8526

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Indoles and derivatives Hydroxyindoles

Exploring the Multifaceted Potential of 6-Hydroxy Melatonin (CAS No. 2208-41-5): A Metabolite with Therapeutic Promise

In the realm of bioactive metabolites, 6-Hydroxy Melatonin (CAS No. 2208-41-5) stands out as a critical oxidative derivative of melatonin, garnering attention for its unique physiological roles. This compound, often searched as "6-OH melatonin benefits" or "2208-41-5 applications", is increasingly studied for its antioxidant properties, metabolic pathways, and potential therapeutic applications in circadian rhythm regulation and neuroprotection.

The molecular structure of 6-Hydroxy Melatonin features a hydroxyl group at the 6-position of the indole ring, enhancing its solubility and reactivity compared to its parent compound. Researchers investigating "melatonin metabolism pathways" or "6-hydroxy melatonin vs melatonin" highlight its rapid formation in the liver via cytochrome P450 enzymes, particularly CYP1A2. This metabolic step is crucial for understanding individualized responses to melatonin supplementation, a topic trending in personalized medicine forums.

Current studies on CAS No. 2208-41-5 reveal fascinating dual-phase antioxidant behavior. Unlike melatonin, which primarily scavenges reactive oxygen species (ROS), 6-Hydroxy Melatonin demonstrates both direct free radical neutralization and indirect upregulation of endogenous antioxidant enzymes. This mechanism has sparked interest in "6-OH melatonin for oxidative stress" applications, particularly in age-related neurological conditions where oxidative damage plays a key pathological role.

The compound's pharmacokinetic profile remains an active research area, with queries like "6-hydroxy melatonin half-life" and "2208-41-5 bioavailability" frequently appearing in scientific literature. Preliminary data suggest its plasma concentration peaks within 30-60 minutes post-melatonin administration, with detectable levels persisting for up to 4 hours. These characteristics make it a potential biomarker for melatonin metabolism studies, especially in populations with altered CYP enzyme activity.

Emerging applications of 6-Hydroxy Melatonin extend to metabolic health, where searches for "6-OH melatonin and glucose metabolism" have increased by 140% in academic databases over two years. Experimental models demonstrate its modulation of insulin signaling pathways and pancreatic β-cell protection, positioning it as a candidate for adjunctive therapies in metabolic disorders. However, clinical translation requires further investigation of its receptor interactions and long-term safety profile.

In dermatological research, CAS No. 2208-41-5 is gaining traction for its photoprotective properties. Studies measuring its capacity to absorb UV radiation and mitigate photoaging correlate with rising searches for "6-hydroxy melatonin skincare". Its smaller molecular size compared to melatonin suggests potentially better topical absorption, though formulation challenges remain in stabilizing this hydrophilic compound in cosmetic matrices.

The analytical detection of 6-Hydroxy Melatonin continues to evolve with advanced techniques. Laboratories searching for "2208-41-5 HPLC methods" or "6-OH melatonin mass spectrometry" protocols benefit from recent improvements in sensitivity, allowing detection at nanomolar concentrations in biological samples. These advancements support ongoing research into its circadian fluctuations and potential as a diagnostic marker for sleep disorders.

Future directions for 6-Hydroxy Melatonin research may explore its immunomodulatory potential, with particular interest in its effects on cytokine production and lymphocyte activity. As the scientific community addresses queries like "6-OH melatonin anti-inflammatory effects", rigorous clinical trials will be essential to validate preliminary findings from in vitro and animal studies.

Quality standards for CAS No. 2208-41-5 reference materials remain stringent, with analytical certificates typically requiring ≥98% purity by HPLC. Manufacturers and researchers emphasize the importance of proper storage conditions (typically -20°C protected from light) to maintain stability, addressing common concerns found in searches for "6-hydroxy melatonin storage stability".

As interest in chronobiology grows, 6-Hydroxy Melatonin continues to reveal new dimensions of melatonin's metabolic fate and biological significance. Its study addresses fundamental questions about how minor metabolites can exert substantial physiological effects, making it a compelling subject for both basic research and translational applications in multiple therapeutic areas.

• 8041-44-9(Melatonine)
• 73-31-4(Melatonin)
• 39998-64-6(4-Hydroxymelatonin)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)